HeartBeam partners with Samsung to boost at-home cardiac care
30 May 2023
HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung.
The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year.
Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a pivotal patent related to artificial intelligence capabilities for its AIMIGo system — a personal, portable vector electrocardiogram (VECG) system. Also, this month, HeartBeam submitted AIMIGo for FDA 510(k) clearance.
This collaborative venture between HeartBeam and Samsung will explore opportunities to leverage HeartBeam’s proprietary technology and expertise in cardiac symptom assessment and monitoring. The two companies think their technologies could boost the standard of cardiac diagnostic capabilities.
HeartBeam’s CEO and founder Branislav Vajdic said the integration of Halo with the AIMIGo telehealth platform could significantly expand product capabilities beyond existing options for at-home cardiac patients.
The collaboration also promises potential engagements with the Department of Veterans Affairs through the Accelerating VA Innovation and Learning (AVAIL) program. HeartBeam’s participation in the AVAIL project will extend its expertise in cardiac symptom monitoring and assessment in collaboration with Samsung to provide innovative solutions for the VA, the largest integrated healthcare system in the U.S.
The potential for AVAIL participation comes from Livmor and Samsung being official collaborators with systems integration company Longview International Technology Solutions (LTS). LTS is one of 17 companies that won spots in a potential five-year, $650 million healthcare technology research and development program for the VA.
Said Kevin Jones, senior director of Federal Healthcare Samsung Electronics America: “The potential of combining Livmor’s technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.